Ondansetrón Fresenius Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetrón Fresenius Kabi, is a serotonin 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is employed to prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetrón Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways. - Chemotherapy‑induced nausea and vomiting: helps reduce the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: provides prophylactic control of emesis. - Post‑operative nausea and vomiting: limits postoperative emesis in patients undergoing general anesthesia.

Adverse reactions to ondansetron are generally mild to moderate, but serious events can occur and require monitoring.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: transient light‑headedness. - Injection site pain: mild discomfort at the infusion site.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with rapid IV administration. - Severe hypersensitivity: rash, urticaria, or anaphylaxis. - Serotonin syndrome: agitation, hyperreflexia, tremor when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Neuroleptic malignant‑like syndrome: rare, high‑fever and muscle rigidity. - Vision changes: blurred vision or visual disturbances.

When using ondansetron, clinicians should consider patient‑specific factors and follow safe handling practices. - Assess cardiac risk: evaluate baseline ECG for QT prolongation. - Review concomitant medications: avoid drugs that also prolong QT interval. - Adjust for hepatic impairment: consider dose reduction in moderate to severe liver disease. - Monitor in pediatric patients: use age‑appropriate dosing and observe for paradoxical reactions. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several drug classes, altering its safety profile or efficacy.

Major Interactions (Avoid): - Other QT‑prolonging agents: concurrent use can increase risk of serious cardiac arrhythmias. - Apomorphine: may cause profound hypotension and loss of consciousness. - Serotonergic drugs (e.g., SSRIs, MAOIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase ondansetron plasma levels. - CYP2D6 substrates (e.g., codeine, metoprolol): ondansetron can modestly raise their concentrations. - Anticholinergic agents: may reduce the anti‑emetic efficacy of ondontion.